CLEAR CELL RENAL CELL CARCINOMA

This large phase 3 trial tested whether taking sorafenib or sunitinib after kidney cancer surgery could prevent the cancer from coming back. Nearly 2000 patients participated. Unfortunately, neither drug improved disease-free survival compared to a placebo, and they caused side e…

This study tested a combination of two drugs (cadonilimab and lenvatinib) given before surgery to 39 people with kidney cancer that was difficult to operate on while saving the kidney. The goal was to shrink the tumor enough to allow a partial, kidney-sparing surgery instead of r…

This early-phase trial tested a new treatment called CTX131 for adults with advanced solid tumors that have not responded to standard therapies. The treatment uses donor immune cells that are gene-edited to target a protein called CD70 found on cancer cells. The study enrolled 19…

This early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…

This study tested a new drug called ARO-HIF2 in 26 people with advanced clear cell kidney cancer that had gotten worse after other treatments. The main goal was to find a safe dose and check for side effects. This is an early-phase trial, so it focuses on safety and dosing, not y…

This early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug…

This study collects blood, tissue, and urine from about 589 people with different types of kidney or urinary tract tumors, plus healthy volunteers. Researchers are looking for special DNA markers (methylated DNA) that could help detect these cancers earlier and more accurately. T…